Journal of Medicinal Chemistry · 1996 · 48 citations · 21 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyLigand BindingPeptide ChemistryPeptide Drug DiscoveryPotency OptimizationReceptor PharmacologyReceptor-ligand InteractionsIntracellular Calcium ReleaseLead Compound OptimizationLead Compound ScreeningLibrary Design For PeptidomimeticsPeptide Analogue DesignPeptide Medicinal ChemistryPeptide Structure - Activity RelationshipsStructure - Activity Relationship Optimization
The use of a dipeptide library as the source of a micromolar chemical lead compound for the human tachykinin NK3 receptor is described. The screening of a dipeptide library through a cloned human NK3 receptor binding assay resulted in the identification of Boc(S)Phe(S)PheNH2 (1), which has subsequently been developed, following a 'peptoid' design strategy, into a series of high-affinity NK3 receptor selective antagonists. The structure-activity relationship of the C-terminal portion of this dipeptide lead was first explored and led to the identification of the urea derivative Boc(S)Phe(R)alphaMePheNH(CH2)7NHCONH2 (41, PD157672). This modified dipeptide has a Ke of 7 nM in blocking senktide-induced increases in intracellular calcium levels in human NK3 receptors stably expressed in CHO cells. Subsequent optimization of the N-terminal BocPhe group and the alphaMePhe residue side chain of 41 led to the identification of [S-(R*,S*)]-[2-(2,3-difluorophenyl)-1-methyl-1-[(7-ureidoheptyl)ca r bamoyl]ethyl]carbamic acid 2-methyl-1-phenylpropyl ester (60, PD161182), a non-peptide NK3 receptor selective antagonist. Compound 60 blocks the senktide-evoked increases in intracellular calcium levels in cloned human NK3 receptors stably expressed in CHO cells with Ke of 0.9 nM.
21
Major Innervation of Newborn Rat Cortex by Monoaminergic Neurons
Joseph T. Coyle, Mark E. Molliver · Science · 1977 · 188 citations